Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data

Figures & data

Table 1 Body weight of wild type mice (+/+) and CB1 knockout mice (−/−) fed a standard diet (SD) or a free choice of SD and high fat diet (SD/HFD) for 12 weeks

Group	Body weight (g)
SD−/−	31.8 ± 1.2
SD/HFD−/−	34.3 ± 2.4
SD+/+	41.1 ± 1.6
SD/HFD+/+	48.6 ± 1.6

Adapted from Ravinet Trillou et al (2004). Results reported as mean + standard error measure. p < 0.05 for SD−/− vs SD+/+; p < 0.05 for SD/HFD+/+ vs SD+/+.

Table 2 Selected placebo subtracted results from rimonabant in obesity (RIO) trials after 1 year. Only shown are those results that are statistically signficant

Measure	RIO-EU	RIO-Lipids	RIO-NA	RIO-DM
Weight (kg)	−4.7	−5.4	−4.7	−3.9
Waist circumference (cm)	−4.2	−4.7	−3.6	−3.3
SBP (mmHg)	ns	−1.8	ns	−2.4
DBP (mmHg)	ns	−1.5	ns	ns
HDL-C (% change)	8.9	8.1	7.2	8.3
TG (%change)	−15.1	−12.4	−13.2	−16.4
Total C:HDL-C ratio	−0.29	−0.32	−0.28	−0.35
Fasting glucose (mmol/L)	−0.06	ns	ns	−0.97
Fasting insulin (μU/mL)	−2.8	−2.6	−2.8	ns
Peak size LDL-C particle (Å)	nr	1.2	nr	nr
Adiponectin (μg/ml)	nr	1.5	nr	nr
Leptin (ng/ml)	nr	−3.8	nr	−3.4
HOMA-IR (%)	−0.7	nr	−0.8	−1.1
CRP (mg/L)	nr	−0.5	nr	−1.4

Data are from ITT-LOCF analysis. Data are placebo subtracted from the 20 mg rimonabant treatment group.

Abbreviations: ns, not significant (p > 0.05); nr, not reported; SBP, systolic blood pressure; DBP, diastolic blood pressure; C, cholesterol; HOMA-IR, insulin resistance measured by homeostasis model assessment; CRP, C-reactive protein.

Table 3 Discontinuations during RIO trials due to any adverse event and due to psychiatric disorders

	Any adverse event		Psychiatric disorders
	Placebo	Rimonabant 20 mg	Placebo	Rimonabant 20 mg
RIO-EU	9.2%	14.5%	5.2%	7.0%
RIO-Lipid	7.0%	15.0%	2.4%	7.6%
RIO-NA	7.2%	12.8%	2.3%	6.2%
RIO-DM	5.5%	15.0%	0.9%	3.6%